CTA-PB Q4 2025 Earnings Call Summary

Q4 Performance: Organic sales decreased by 4% year-over-year, with Crop Protection volumes down 2% and prices down 1%. Seed prices increased by 3%, but volumes fell by 8% due to timing shifts.
Full Year Results: Organic sales increased by 4%, with operating EBITDA rising 14% to $3.85 billion, achieving an operating EBITDA margin of over 22%, a 215 basis point improvement.
Free Cash Flow: Improved to $2.9 billion, up $1.2 billion from the previous year, driven by higher earnings and working capital discipline.
SG&A and R&D: SG&A expenses rose significantly, from $735 million to $860 million, primarily due to higher compensation expenses. R&D expenses increased by $50 million.

Separation Update: Corteva is on track for a spin-off in Q4 2026, with a new CEO search underway and plans to announce leadership teams and brand identity for SpinCo.
Bayer Agreement: A comprehensive resolution with Bayer allows Corteva to accelerate its corn licensing business and enter the cotton market, projecting $1 billion in earnings upside over the next decade.
Seed Business Performance: Strong organic growth across all regions, with significant improvements in cost and royalty income, particularly in North America corn and soybean licensing in Brazil.
Crop Protection Pipeline: A robust $9 billion pipeline of differentiated technologies, with expectations for modest market growth in 2026.

2026 Guidance: Operating EBITDA is projected to be between $4 billion and $4.2 billion, reflecting a 7% increase from 2025. Operating EPS is expected to be between $3.45 and $3.70 per share.
Market Expectations: Continued growth in Seed and Crop Protection volumes, driven by new products and biologicals, with a focus on improving net royalty expenses and productivity actions.

Q4 Declines: The fourth quarter saw declines in both sales and operating EBITDA compared to the previous year, attributed to lower volumes and higher compensation expenses.
Competitive Pricing Pressures: Ongoing pricing pressures in Crop Protection markets, particularly in Latin America and Asia Pacific, due to competitive dynamics.
Tariff Headwinds: An estimated $80 million impact from tariffs is expected in 2026, which could affect profitability.
Farmer Financial Stress: Farmers in Latin America are experiencing tight cash flows due to high interest rates and suppressed commodity prices, which may impact purchasing behavior.

Bayer Agreement Clarifications: The agreement enhances Corteva's licensing capabilities and resolves litigation, providing clarity and operational freedom.
Gene Editing Potential: There is optimism regarding regulatory changes in Europe that could facilitate the introduction of gene-edited products, with a focus on multi-disease resistant corn expected to be commercialized within 1-2 years.
Market Share Gains: Corteva reported share gains in corn and soybeans in North America and Brazil, with expectations to double Conkesta's market share in Brazil in 2026.
Productivity Improvements: A commitment to $200 million in productivity benefits for 2026, with ongoing opportunities for cost improvements across both Seed and Crop Protection segments.

This summary encapsulates Corteva's financial performance, strategic initiatives, outlook, and challenges as discussed in the Q4 2025 earnings call.

CTA-PB — E. I. du Pont de Nemours and Company